跳至主要内容
临床试验/ACTRN12618001763235
ACTRN12618001763235尚未招募1 期

Pharmacokinetics of ingested Ursolic Acid supplements in healthy men

Garvan Institute of Medical Research0 个研究点目标入组 8 人开始时间: 2018年10月25日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 35 Years(—)
性别
Male

入选标准

  • Healthy men aged between 18-35 years
  • A BMI >18 and <27.99 kg/m2

排除标准

  • A BMI < 17.99 or > 28 kg/m2
  • Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event
  • Clinically significant (>2 × upper limit of normal [ULN]) abnormal blood test result at screening for any metabolite measured from: Full Blood Count, Urea & Electrolytes, Thyroid Function Tests, Coagulation Tests, Liver Function Tests, glucose, insulin, HbA1c, DBIL, TBIL, phosphate, calcium and Creatine Kinase.
  • Taking beta-adrenergic blocking agents, statins or non-steroidal anti-inflammatory drugs
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
  • Respiratory disease including pulmonary hypertension, COPD, asthma or an FEV1 less than 1.5L
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing’s disease, types 1 or 2 diabetes
  • Active inflammatory bowel or renal disease
  • Malignancy
  • Recent steroid treatment (within 6 months), or hormone replacement therapy
  • Family history of early (<55y) death from cardiovascular disease
  • Taking any prescription/ non-prescription medication / supplements that in the opinion of the CI or PI might interact with or impact UA absorption or metabolism
  • Current or recent (last 30 days) smoker
  • Known or possible sensitivity to Ursolic Acid (allergy to apples, rosemary plant, holy basil or bearberry).
  • Planned surgery during the course of the trial;
  • History of or current diagnosis of any cancer (except successfully treated basal cell carcinoma or cancer in full remission >5 years after diagnosis);
  • History of blood/bleeding disorders;
  • Participation in another clinical research trial within 30 days before randomization

研究者

相似试验